Gene therapy: advances, challenges and perspectives
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The ability to make site-specific modifications to the human genome has been an objective in medicine since the recognition of the gene as the basic unit of heredity. Thus, gene therapy is understood as the ability of genetic improvement through the correction of altered (mutated) genes or site-specific modifications that target therapeutic treatment. This therapy became possible through the advances of genetics and bioengineering that enabled manipulating vectors for delivery of extrachromosomal material to target cells. One of the main focuses of this technique is the optimization of delivery vehicles (vectors) that are mostly plasmids, nanostructured or viruses. The viruses are more often investigated due to their excellence of invading cells and inserting their genetic material. However, there is great concern regarding exacerbated immune responses and genome manipulation, especially in germ line cells. In vivo studies in in somatic cell showed satisfactory results with approved protocols in clinical trials. These trials have been conducted in the United States, Europe, Australia and China. Recent biotechnological advances, such as induced pluripotent stem cells in patients with liver diseases, chimeric antigen receptor T-cell immunotherapy, and genomic editing by CRISPR/Cas9, are addressed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These viruses show good safety when administered to target tissues, do not integrate in the recipient genome, successfully transduce retinal cells, and can carry genes of around 30 kb long.4,29,54–56”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [54]
In the citing paper
“However, these vectors tend to be rapidly cleared due to the presence of neutralizing antibodies from pre-existing immunity.4,29,54–56”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [54]
In the citing paper
“The AAV vectors are a common vector choice in ocular and non-ocular gene therapies, offering benefits such as a long duration of transgene expression, extremely low risk of insertional mutagenesis, only a mild inflammatory response, and low possibility of germline transmission.29,54”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [54]
In the citing paper
“However, they carry risks for insertional mutagenesis and germline transmission and may elicit more inflammatory responses than AAVs.54,56,73”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“For example, the CD19 antigen can be found in normal or malignant B cells, and the CAR design for the CD19 target in not capable of distinguishing them.(20,22) Other common toxicity for CAR-T therapy (and many other types of immunotherapy for cancer) is the cytokine release syndrome (CRS).”
BackgroundCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“Activation of the immune system after CAR-T infusion can induce a rapid increase in the levels of inflammatory cytokines.(20,23) New developments in the design of vectors and trials with CAR-T provide balance and reinforcement in safety for amplification of the clinical application.”
BackgroundEshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4407 · Cited by 1,575
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea
Marraffini, L. A., & Sontheimer, E. J. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2749 · Cited by 919
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Research works printed but not linked: 4
- Mukherjee S, 2016, Genetic therapies: posthuman gene therapy
- Linden R, 2010, Gene therapy: what it is, what it is not and what it will be, Estud Av, 24, 31
- Parham P, 2009, Antigen recognition by T lymphocytes
- Vieira GV, 2016, Visão geral do mecanismo básico de ação
Cited by
Recent advances in the development of gene delivery systems.
Sung, Y., & Kim, S. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0156-z · Cited by 458
Gene therapy: Comprehensive overview and therapeutic applications
Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120375 · Cited by 337
Stimuli-Responsive Materials for Tissue Engineering and Drug Delivery
Municoy, S., Álvarez Echazú, M. I., Antezana, P. E., Galdopórpora, J. M., Olivetti, C., Mebert, A. M., Foglia, M. L., Tuttolomondo, M. V., Alvarez, G. S., Hardy, J. G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134724 · Cited by 289
Biologics, theranostics, and personalized medicine in drug delivery systems
Puccetti, M., Pariano, M., Schoubben, A., Giovagnoli, S., & Ricci, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107086 · Cited by 212
Magnetite Nanoparticles in Magnetic Hyperthermia and Cancer Therapies: Challenges and Perspectives
Włodarczyk, A., Gorgoń, S., Radoń, A., & Bajdak-Rusinek, K. (2022) · Nanomaterials · doi:10.3390/nano12111807 · Cited by 209
Metadata
- Authors
- Gonçalves, G. A. R., & Paiva, R. D. M. A.
- Affiliations
- Hospital Israelita Albert Einstein, Brazil
- Hospital Israelita Albert Einstein (BR)
- Venue
- Einstein (São Paulo)
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2017-09
- Volume
- 15
- Issue
- 3
- Pages
- 369-375
- ISSN
- 1679-4508 (ISSN-L)
- PMC
- PMC5823056
- OpenAlex
- W2944013917
- Cited by
- 351
- References
- 27
- Citations by year
- 2026: 25 · 2025: 47 · 2024: 76 · 2023: 63 · 2022: 55 · 2021: 39 · 2020: 23 · 2019: 16 · 2018: 6
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Einstein (São Paulo) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- gene therapy, gene delivery vectors, viral vectors, plasmid vectors, genome editing, CRISPR/Cas9, induced pluripotent stem cells, liver disease, immune response to gene therapy, clinical trials, somatic cells, germline modification
- MeSH terms
- Gene Editing, Animals, Genetic Vectors, Humans, Receptors, Antigen, T-Cell, Genetic Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy: advances, challenges and perspectives. https://app.cochat.ai/papers/10.1590/s1679-45082017rb4024
- The paper
- Gonçalves, G. A. R., & Paiva, R. D. M. A. (2017). Gene therapy: advances, challenges and perspectives. Einstein (São Paulo). https://doi.org/10.1590/s1679-45082017rb4024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.